1. News

Retinal Disorder Treatment Market Structure, Industry Inspection, and Forecast 2027

Disclaimer: This is a user generated content submitted by a member of the WriteUpCafe Community. The views and writings here reflect that of the author and not of WriteUpCafe. If you have any complaints regarding this post kindly report it to us.

The global retinal disorder treatment market size is projected to expand at a substantial CAGR during the forecast period, 2021-2028. The growth of the market is attributed to the increasing funding by regulatory bodies for researching ocular disorders.

According to the National Eye Institute, diabetic retinopathy may affect approximately 10 million and 14 million people in the US by 2030 and 2050, respectively. In 2017, NCBI published that the number of people with early and late age-related macular degeneration (AMD) in Europe is expected to be in between 14.9 and 21.5 million and between 3.9 and 4.8 million, respectively, by 2040. The data published in the World Population Prospects: 2019 Revision states that approximately one in 11 and one in four people in North America and Europe, respectively, will be aged 65 or older by 2050.

Retinal Disorder Treatment Market Segment Insights

Based on types, the market is divided into macular degeneration, diabetic retinopathy, and others. The macular degeneration is further divided into dry macular degeneration and wet macular degeneration. The macular degeneration segment is expected to account for a key market share during the forecast period owing to the introduction of innovative products for the treatment of macular degeneration. Additionally, rising awareness of this type of retinal disorder is expected to drive the market growth during the forecast period. For instance, in February 2019, Bausch & Lomb announced the launch of SightMatters.com, a new educational online resource for people with age-related macular degeneration. According to the International Agency for the Prevention of Blindness, AMD is expected to affect approximately 196 million people worldwide by 2020.

On the basis of dosage forms, the retinal disorder treatment market is segmented into gels, eye solutions, capsules & tablets, eye drops, and ointments. The eye solutions segment is expected to account for a significant market share during the forecast period. Several eye injections, such as Lucentis and EYLEA, are available for the treatment of retinal diseases. However, the eye drop segment is anticipated to expand at a rapid pace during the forecast period owing to cost-effectiveness and growing number of programs to create new AMD eye drops. For instance, in March 2018, PanOptica reported that it is undergoing phase 2/3 clinical trials for PAN-90806, a topically applied eye drops for the treatment of wet AMD.

In terms of distribution channels, the retinal disorder treatment market is segregated into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment is expected to exhibit a high CAGR during the forecast period owing to the presence of high-quality treatment and value-based care to a large pool of patients. Apart from that, this segment is being driven by improving healthcare plans and favourable reimbursement policies. Growing investments in healthcare infrastructure in developing and underdeveloped economies is fueling the segment growth.

The online pharmacy segment is anticipated to expand at a rapid pace during the forecast period owing to increasing patient awareness about the advantages of online pharmacy, such as lower prices, convenience, and expert advice and counselling, among patients with retinal problems. According to a 2017 survey performed by the Alliance for Safe Online Pharmacies Global, 33% of survey participants acquired prescription medications from an online pharmacy in the US.

On the basis of regions, the retinal disorder treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. The regional market growth is attributed to increasing prevalence of retinal disorders. According to study published on WebMD in 2019, AMD affects 25% of the general population in the US and more than 10% of the population aged between 65 and 74 years. However, the market in Asia Pacific is expected to exhibit a robust CAGR during the forecast period owing to high unmet clinical demands, the availability of effective treatment modalities, rising disposable income, and increasing awareness about early diagnosis in emerging countries.

Get Sample Report @ Request For Sample of Retinal Disorder Treatment Market – Global Industry Analysis, Growth, Share, Size, Trends, and Forecast | Growth Market Reports

Key Players Covered in the Report

Santen Pharmaceutical Co., Ltd., REGENERON, Graybug Vision, Inc., Shire (Takeda Pharmaceuticals), Bayer AG, Genentech, Inc., Acucela Inc., and Pfizer Inc.

About Growth Market Reports:

Growth Market Reports provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. Growth Market Reports has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.


Growth Market Reports
Phone: +1 909 414 1393
Email: sales@growthmarketreports.com
Web: https://growthmarketreports.com
Follow Us: LinkedIn | Twitter


Welcome to WriteUpCafe Community

Join our community to engage with fellow bloggers and increase the visibility of your blog.
Join WriteUpCafe